Entity
  • Surface Oncology Inc.

    Created in 2014
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    1,015 9,475
  • Activities

  • Technologies

  • Entity types

  • Location

    50 Hampshire St 8th Floor, Cambridge, MA 02139, USA

    Cambridge

    United States of America

  • Employees

    Scale: 51-200

    Estimated: 23

  • Engaged corporates

    2
    1 0
  • Added in Motherbase

    5 years, 7 months ago
Description
  • Value proposition

    #lifeunderthesurface
    #BBJBestPlacesToWork2023,2022,2021
    #BostonGlobeTopPlacesToWork2023,2022,2021

    Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors"​, have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required.
    We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
    Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work.
    From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.

  • Surface Oncology | Break Through

    Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer.

  • http://www.surfaceoncology.com
Corporate interactions BETA
Corporate TypeTweets Articles
Vertex Pharmaceuticals
Vertex Pharmaceuticals
Biotechnology, Biotechnology Research
Vertex Pharmaceuticals
Biotechnology, Biotechnology Research
Other

6 Dec 2021


Nasdaq
Nasdaq
Finance, Financial Services
Nasdaq
Finance, Financial Services
Capitalistic
Not partnership
Event

11 May 2018


Similar entities
Loading...
Loading...
Social network dynamics